Note As at 31 Dec 2024 $’000 As at 31 Dec 2023 $’000 Assets Current assets Cash and cash equivalents 10 3,153 17,094 Short term investments 11 219,089 211,445 Trade and other receivables 12 157,967 5,817 Contract assets 13 17,756 12,800 Derivative financial instruments 15 1,362 – Total current assets 399,327 247,156 Non-current assets Plant and equipment 31 43 Deferred tax asset 8 10,348 771 Total non-current assets 10,379 814 Total assets 409,706 247,970 Liabilities Current liabilities Trade and other payables 14 2,895 3,418 Derivative financial instruments 15 – 2,226 Income tax payable 8 42,866 37,119 Total current liabilities 45,761 42,763 Non-current liabilities Employee benefits 14 41 – Total non-current liabilities 41 – Total liabilities 45,802 42,763 Net assets 363,904 205,207 Equity Share capital 16 165,270 173,127 Share option reserve 4,695 4,382 Currency translation reserve 13,508 (10,690) Retained earnings 180,431 38,388 Total equity 363,904 205,207 CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2024 The above consolidated statement of financial position should be read in conjunction with the accompanying notes Neuren Pharmaceuticals Limited Annual Report 2024 25
RkJQdWJsaXNoZXIy MjE2NDg3